Adverse effects of human immunoglobulin therapy

Transfusion Medicine Reviews

Volumn 27, Issue 3, 2013, Pages 171-178

  Stiehm, E Richard ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; ERYTHROCYTE ANTIBODY; HUMAN IMMUNOGLOBULIN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PROCOAGULANT;

ANAPHYLAXIS; ANTIGENICITY; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD CELL COUNT; CHEST TIGHTNESS; CHILL; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; ENTERITIS; FEVER; HEADACHE; HEMOLYSIS; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; INFECTION PREVENTION; INFUSION RATE; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; KIDNEY FAILURE; LUNG DISEASE; PREMEDICATION; PRURITUS; RISK FACTOR; SHOCK; SKIN DISEASE; SUBSTITUTION THERAPY; THROMBOEMBOLISM; URTICARIA; WHEEZING;

EID: 84880713148     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2013.05.004     Document Type: Article

References (129)

1. Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002, 2:368-378.
2. Eibl M.M. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008, 28:737-764.
3. Stokes J., Neefe J.R. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945, 127:144-145.
4. Bruton O.C. Agammaglobulinemia. Pediatrics 1952, 9:722-728.
5. Barandun S., Kistler P., Jeunet F., Islaker H. Intravenous administration of human γ-globulin. Vox Sang 1962, 7:157-174.
6. Stiehm E.R., Keller M.A. Passive immunization. Textbook of pediatric infectious diseases 2009, 3182-3202. WB Saunders, Philadelphia. 6th ed. R. Feigin, J.D. Cherry, G.J. Demmler, S.L. Kaplan (Eds.).
7. Ammann A.J., Ashman R.F., Buckley R.H., Hardie W.R., Krantman H.J., Nelson J., et al. Use of intravenous gamma globulin in antibody immunodeficiency. Results of a multicenter controlled trial. Clin Immunol Immunopathol 1982, 22:60-67.
8. Imbach P., Barundun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 1:1228-1231.
9. Furusho K., Sato K., Soeda T., Okabe T., Hirata T., Kawada S. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983, 2:1359.
10. Feasby T., Banwell B., Benstead T., Bril V., Brouwers M., Freedman M., et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007, 21(2 Suppl 1):S57-S107.
11. Berger M., Cupps T.R., Fauci A.S. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980, 93:55-56.
12. Ugazio A.G., Duse M., Re R., Mangili G., Burgio G.R. Subcutaneous infusion of gammaglobulins in management of agammaglobulinemia. Lancet 1982, 1:226.
13. Roord J.J., vander Meer J.W.M., Kuis W., de Windt G.E., Zegers B.J., van Furth R., et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet 1982, 1:689-690.
14. Gardulf A., Hammarstrom L., Smith C.I.E. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991, 338:162-166.
15. Chapel H.M., Spickett G.P., Ericson D., Engle W., Eibl M.M., Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20:94-100.
16. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004, 112:1-7.
17. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007, 21:106-116.
18. Abolhassani H., Sadaghiani M.S., Aghamohammadi A., Ochs H.D., Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: Systematic review and meta analysis. J Clin Immunol 2012, 6:1180-1192.
19. Wasserman R.L. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol 2012, 6:1153-1164.
20. Ameratunga R., Sinclair J., Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 2004, 136:111-113.
21. American Academy of Pediatrics Red book: report of the committee on infectious diseases 2012, 1-1058. American Academy of Pediatrics, [Elk Grove Village, IL]. 29th ed. L.K. Pickering, C.J. Baker, D.W. Kimberlin, S.S. Long (Eds.).
22. Stiehm E.R., Ochs H.D., Winkelstein J.A. General considerations. Immunologic disorders in infants and children. 5th ed. 5 2004, 289-355. Saunders/Elsevier, Philadelphia. E.R. Stiehm, H.D. Ochs, J.A. Winkelstein (Eds.).
23. Duhem C., Dicato M.A., Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994, 97(Suppl 1):79-83.
24. Nydegger U.E., Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999, 3:171-178.
25. Pierce L.R., Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003, 17:241-251.
26. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin. Adverse effects and safe administration. Clin Rev Allergy Immunol 2006, 29:173-184.
27. Bonilla F.A. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008, 122:1238-1239.
28. Shroeder H.W., Dougherty C.J. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012, 40:601-611.
29. Struff W.G., Klasser M., Eckert V., Dietrich R.L. Safety monitoring of a polyvalent immunoglobulin preparation: documentation of 15,548 administrations. Int J Clin Pharmacol Ther 2005, 43:420-428.
30. Brennan V.M., Salome-Bentley N.J., Chapel H.M. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Lancet 2003, 133:247-251.
31. Chapel H.M., Lee M., Hargreaves R., Pamphilion D.H., Prentice A.G. Randomized trial of intravenous immunoglobulin prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994, 343:1059-1063.
32. Singh-Grewal D., Kemp A., Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006, 91:651-654.
33. Donofrio P.D., Bril V., Dalakas M.C., Deng C., Hanna K., Hartung H.P., et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010, 67:1082-1088.
34. Kishiyama J.L., Valacer D., Cunningham-Rundles C., Sperber K., Richmond G.W., Abramson S., et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 1999, 91:126-133.
35. Sekul E.A., Cupler E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994, 121:259-262.
36. Hommes O.R., Sorensen P.S., Fazekas F., Enriquez M.M., Koelmel H.W., Fernandez O. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomized placebo-controlled trial. Lancet 2004, 364:1149-1156.
37. Misbah S., Sturzenegger M.H., Borte M., Shapiro R.S., Wasserman R.L., Berger M., et al. Subcutaneous immunoglobulin. Opportunities and outlook. Clin Exper Immunol 2009, 158(Suppl 1):51-59.
38. Borte M., Quinti I., Soresina A., Fernandez-Cruz E., Ritchie B., Schmidt D.S., et al. Efficacy and safety of subcutaneous Viviglobin replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol 2011, 31:952-961.
39. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: A retrospective analysis. J Clin Immunol 2010, 30:301-307.
40. Welch M.J., Stiehm E.R. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol 1983, 3:285-286.
41. Sundin U., Nava S., Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998, 112:341-346.
42. Vyas G.N., Perkins H.A., Fudenberg H.H. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 1968, 2:312-315.
43. Burks A.W., Sampson H.A., Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986, 314:560-564.
44. Hammarstrom L., Smith C.I.E. Anaphylaxis after administration of gamma globulin for hypogammaglobulinemia. N Engl J Med 1986, 315:519-520.
45. Rachid R., Bonilla F.A. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012, 129:628-634.
46. Kato E., Shindo S., Eto Y., Hashimoto N., Yamamoto M., Sakata Y., et al. Administration of immune globulin associated with aseptic meningitis. JAMA 1988, 259:3269-3271.
47. Scribner C.L., Kapit R.M., Phillips E.T., Rickles N.M. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994, 121:305-306.
48. Kaarthigeyan K., Burli V.V. Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency. J Pediatr Neurol 2011, 6:160-161.
49. Jarius S., Eichhorn P., Albert M.H., Wagenpfeil S., Wick M., Belohradsky B.H., et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor-independent way. Blood 2007, 109:4378-4382.
50. Veranneman N., Van Raemdonck D., Dupont L., Verlede G. Repeated, severe headache in a lung transplant patient: a case report. Acta Clin Belg 2010, 65:269-270.
51. Wada Y., Kamei A., Fuji Y., Ishikawa K., Chida S. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease. J Pediatr 2006, 148:399-400.
52. Okuda D., Flaster M., Frey J., Sivakumar K. Arterial thrombosis induced by IVIg and its treatment with tissue plasminogen activator. Neurology 2003, 60:1825-1826.
53. Al-Riyami A.Z., Lee J., Connolly M., Shereck E. Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura. Pediatr Blood Cancer 2011, 57:157-159.
54. Barada W., Muwakkit S., Hourani R., Bitar M., Mikati M. Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: a case report. Neuropediatrics 2008, 39:131-133.
55. Iroh Tam P.Y., Richardson M., Grewal S. Fatal case of bilateral internal jugular vein thrombosis following IVIg infusion in an adolescent girl treated for ITP. Am J Hematol 2008, 83:323-325.
56. Voltz R., Rosen F.V., Yousry T., Beck J., Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996, 46:250-251.
57. Barton J.C., Herrera G.A., Galla J.H., Bertoli L.F., Work J., Koopman W.J. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987, 82:624-629.
58. Jordan S.C. Intravenous γ-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 1989, 53:S164-S169.
59. Schifferli J., Leski M., Farve H., Imbach P., Nydegger U., Davies K. High-dose intravenous IgG treatment andrenal function. Lancet 1991, 337:457-458.
60. Centers for Disease Control, Prevention (CDC) Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999, 48:518-521.
61. Rault R., Piraino B., Johnston J.R., Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991, 36:83-86.
62. Chacko B., John G.T., Balakrishnan N., Kirubakara M.G., Jacob C.K. Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 2006, 28:193-195.
63. Ahsan N., Palmer B.F., Wheeler D., Greenlee R.S., Toto R.D. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994, 154:1985-1987.
64. Welles C.C., Tambra S., Lafayette R.A. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010, 55:148-151.
65. Woodruff R.K., Grigg A.P., Firkin F.C., Smith I.L. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986, 2:217-218.
66. Paran D., Herishanu Y., Elkayam O., Shopin L., Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005, 16:313-318.
67. Caress J.B., Houston-Webb L., Passmore L.V., Finkbiner A.P., Cartwright M.S. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009, 256:339-342.
68. Cordonnier C., Chevret S., Legrand M., Rafi H., Dhedin N., Lehmann B., et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003, 139:8-18.
69. Huang L., Kanellis J., Mulley W. Slow and steady: reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. Nephrology 2011, 16:239-242.
70. Go R.S., Call T.G. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29:73-84.
71. Hommes O.R., Sorensen P.S., Fazekas F., Enriquez M.M., Koelmel H.W., Fernandez O., et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomized placebo-controlled trial. Lancet 2004, 1149-1156.
72. Mignogna M.D., Fortuna G., Leuci E., Ruoppo E., Adamo D., Fedele S. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases. Clin Experiment Dermatol 2008, 34:145-150.
73. Daniel G.W., Menis M., Sridhar G., Scott D., Wallace A.E., Ovanesov M.V. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 2012, 52:2113-2121.
74. Marie I., Maurer G., Herve F., Hellot M.-F., Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature. Br J Dermatol 2006, 155:714-721.
75. Mizrahi M. The hypercoagulability of intravenous immunoglobulin. Clin Adv Hematol Oncol 2011, 9:49-50.
76. Fisman D.N., Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997, 8:775-777.
77. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994, 44:223-226.
78. Reinhart W.H., Berchtold P.E. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992, 339:662-664.
79. Wolberg A.S., Kon R.H., Monroe D.M., Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000, 65:30-34.
80. Okuda D., Flaster M., Frey J., Sivakumar K. Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 2003, 60:1825-1826.
81. Oberman H.A., Beck M.L. Red blood cell sensitization due to unexpected Rh antibodies in immune serum globulin. Transfusion 1971, 11:382-384.
82. Lang G.E., Veldhuis B. Immune serum globulin: a cause for anti-Rho(D) passive sensitization. Am J Clin Pathol 1973, 60:205-207.
83. Copelan E.A., Strohm P.L., Kennedy M.S., Tutschka P.J. Hemolysis following intravenous immune globulin therapy. Transfusion 1986, 26:410-412.
84. Moscow J.A., Casper A.J., Kodis C., Fricke W.A. Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion 1987, 27:248-249.
85. Morgan S., Sorensen P., Vercellotti G., Zantek N.D. Haemolysis after treatment with intravenous immunoglobulin due to anti-A. Transfus Med 2011, 21:267-270.
86. Thomas M.J., Misbah S.A., Chapel H.M., Jones M., Elrrington G., Newsom-Davic J. Hemolysis after high-dose intravenous Ig. Blood 1993, 82:3789.
87. Daw Z., Padmore R., Neurath D., Cober N., Tokessy M., Dejardins D., et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008, 48:1598-1601.
88. o(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005, 106:1532-1537.
89. Anderson D., Ali K., Blanchette V., Brouwers M., Couban S., Radmoor P., et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007, 21:S9-S56.
90. Gerebenau M.D. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992, 362:271.
91. Ben-Chetrit E., Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992, 362:270.
92. Matsuda M., Hosoda W., Sekijima Y., Hoshi K., Hashimoto T., Itoh S., et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol 2003, 26:306-311.
93. von Gunten S., Schaub A., Vogel M., Stadler B.M., Miescher S., Simon H. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006, 108:4255-4259.
94. Lassiter H.A., Bibb K.W., Bertolone S.J., Patel C.C., Stroncek D.F. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol 1993, 15:120-123.
95. Rizk A., Gorson K.C., Kenney L., Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001, 41:64-68.
96. Moalic V., Vaillant C., Ferec C. Transfusion related acute lung injury (TRALI): an unrecognized pathology [In French]. Pathol Biol (Paris) 2005, 53:111-115.
97. Berger-Achituv S., Ellis M.H., Curtis B.R., Wolach B. Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent. Am J Hematol 2008, 83:676-678.
98. Nguyen M.K., Rastogi A., Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. Clin Exp Nephrol 2006, 10:124-126.
99. Palevsky P.M., Rendulic D., Diven W.F. Maltose-induced hyponatremia. Ann Intern Med 1993, 118:526-528.
100. Lawn N., Wijdicks E.F.M., Burrit M.F. Intravenous immune globulin and pseudohyponatremia. N Engl J Med 1998, 339:632.
101. Figuera-Aloy J., Rodriguez-Miguelez J.M., Iriondo-Sanz M., Salvai-Roiges M.D., Botet-Mussons F., Carbonell-Estrany X. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics 2010, 125:139-144.
102. Krishnan L., Pathare A. Necrotizing enterocolitis in a term neonate following intravenous immunoglobulin therapy. Indian J Pediatr 2011, 78:743-744.
103. Ignace-Girerd S., Bouffard J., Du Besset A.C., Giannoli C., Cahen R., Dijoud F., et al. Reversible ileitis secondary to high dose intravenous immunoglobulin in adult kidney transplant patient treated for acute humoral rejection. Transpl Int 2011, 24:e111-e114.
104. Centers for Disease Control and Prevention (CDC) Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994, 43:505-509.
105. Schiff R.I. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994, 331:1607.
106. Bjoro K., Froland S.S., Yun Z., Samdal H.H., Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994, 331:1607-1611.
107. Chapel H., Christie J., Peach V., Chapman R.W. Five year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001, 99:320-324.
108. Razvi S., Schneider L., Jonas M.M., Cunningham-Rundles C. Outcome of intravenous Immunoglobulin-transmitted hepatitis C virus (HCV) in primary immunodeficiency. Clin Immunol 2001, 101:284-288.
109. Hayakawa F., Imada K., Towatari M., Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002, 118:1187-1189.
110. Stiehm E.R., Keller M.A., Vyas G.N. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals 2008, 36:363-374.
111. Erdman D.D., Anderson B.C., Torok T.J., Finkel T.H., Anderson L.J. A possible transmission of parvovirus B19 from intravenous immune globulin. J Med Virol 1997, 53:233-236.
112. Zou S., Fang C.T., Schonberger L.B. Transfusion transmission of human prion diseases. Transfus Med Rev 2008, 22:58-69.
113. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
114. Burdick M.D., Pifat D.Y., Petteway S.R., Cai K. Clearance of prions during plasma protein manufacture. Transfus Med Rev 2006, 20:57-62.
115. Ziegner U.H., Kobayashi R.H., Cunningham-Rundles C., Espanol T., Fasth A., Huttenlocher A., et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol 2002, 102:19-24.
116. Vecchietti G., Kerl K., Prins C., Kaya G., Saurat J.H., French L.E. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol 2006, 142:213-217.
117. Iannaccone S., Sferrazza B., Quattrini A., Smirne S., Ferini-Strambi L. Pompholyx (vesicular eczema) after IV immunoglobulin therapy for neurologic disease. Neurology 1999, 53:1154-1155.
118. Barucha C., McMillan J.C. Eczema after intravenous infusion of immunoglobulin. Br Med J 1987, 295:1141.
119. Chan Lam D., Fitzsimons E.J., Douglas W.S. Alopecia after immunoglobulin infusion. Lancet 1987, 1:1436.
120. Rodeghiero F., Castaman G., Vespignani M., Dini E., Bertazzoni M. Erythema multiforme after intravenous immunoglobulin. Blut 1988, 56:145.
121. Uyttendaele H., Obadiah J., Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol 2003, 3:337-340.
122. Barbaud A., Trechot P., Granel F., Lonchamp P., Faure G., Schmutz J.L., et al. A baboon syndrome induced by intravenous immunoglobulins: report of a case and immunological analysis. Dermatology 1999, 199:258-260.
123. Ayliffe W., Haeney M., Roberts S.C., Lavin M. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Lancet 1992, 339:558-559.
124. Duhem C., Ries F., Dicato M. Intravenous immune globulins and hypothermia. Am J Hematol 1996, 51:172-173.
125. Craig T.J., Davis W. Hepatitis associated with high dose intravenous gammaglobulin. Ann Allergy 1993, 71:276.
126. Lisak R.P. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996, 135:85-88.
127. Kim D., Siewiesk S. Sidestepping maternal antibody: a lesson from measles vaccination. Expert Rev Clin Immunol 2011, 7:557-559.
128. Amer J., Ott E., Ibbott F.A., O'Brien D., Kempe C.H. The effect of monthly γ-globulin administration on morbidity and mortality from infection in premature infants during the first year of life. Pediatrics 1963, 32:4-9.
129. Stiehm E.R., Orange J.S., Ballow M., Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr 2010, 57:185-218.